Nomura India maintained its 'Buy' rating on Cipla Ltd, setting a target price of Rs 1,780 by March 2026. Cipla anticipates ...

Cipla has secured USFDA approval to market a generic cancer treatment, specifically paclitaxel protein-bound particles.

Pharma major Cipla will release its Q4 FY25 earnings on May 13, 2025. The Board may also consider a final dividend for FY25.

Drug major Cipla on Friday said it has received approval from the US health regulator to market a generic cancer treatment drug. The company has received the final approval from the US Food and ...

Cipla has launched an innovative combination ... tenofovir 300 mg and emtricitabine 200mg comprise the drug Viraday. Viraday, one tablet of which alone effectively treats a HIV infected person ...

Cipla is facing moderate headwinds at the moment. India business underwent a soft two quarters, US business faced supply issues in one main product and Trump tariff pressure has impacted the ...